Current Protein Identity：P48552
New Search
Difference tags compare only the current result set; every original PDB and assembly record remains separate.
Related-Structure Differences
Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.
| PDB Entry | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Experimental Method | Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 2GPO Estrogen Related Receptor-gamma ligand binding domain complexed with a synthetic peptide from RIP140 Deposited 2006-04-18 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain C
366–390（25 aa）
Fragment：LXXLL Motif (Residues 366-390)
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.2；295 K；14% PEG 3350
0.2M sodium formate, pH 7.2, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.95 Å R-free 0.231 |
| 2GPP Estrogen Related Receptor-gamma ligand binding domain complexed with a RIP140 peptide and synthetic ligand GSK4716 Deposited 2006-04-18 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain C
366–390（25 aa）
Fragment：Residues (366-390)
Chain D
366–390（25 aa）
Fragment：Residues (366-390)
|
Not recorded | 1BA 4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；9% PEG 20K 0.1M MES buffer, pH 7.5, vapor diffusion, hanging drop, temperature 295K
|
Resolution 2.60 Å R-free 0.257 |
| 4S14 Crystal structure of the orphan nuclear receptor RORgamma ligand-binding domain in complex with 4alpha-caboxyl, 4beta-methyl-zymosterol (4ACD8) Deposited 2015-01-07 | Assembly 1 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric（12） Consistent with protein count |
Chain C
499–510（12 aa）
Fragment：LxxLL binding motif
|
Not recorded | 4D8 (3beta,4alpha,5beta,14beta)-3-hydroxy-4-methylcholesta-8,24-diene-4-carboxylic acid × 6 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；282 K；0.3M Potassium sodium tartrate, pH 8, VAPOR DIFFUSION, SITTING DROP, temperature 282K
|
Resolution 3.54 Å R-free 0.219 |
| 4S14 Crystal structure of the orphan nuclear receptor RORgamma ligand-binding domain in complex with 4alpha-caboxyl, 4beta-methyl-zymosterol (4ACD8) Deposited 2015-01-07 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
499–510（12 aa）
Fragment：LxxLL binding motif
|
Not recorded | 4D8 (3beta,4alpha,5beta,14beta)-3-hydroxy-4-methylcholesta-8,24-diene-4-carboxylic acid × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；282 K；0.3M Potassium sodium tartrate, pH 8, VAPOR DIFFUSION, SITTING DROP, temperature 282K
|
Resolution 3.54 Å R-free 0.219 |
| 4S15 Crystal structure of the orphan nuclear receptor RORalpha ligand-binding domain in complex with 4alpha-caboxyl, 4beta-methyl-zymosterol (4ACD8) Deposited 2015-01-08 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
499–510（12 aa）
Fragment：LxxLL binding motif
|
Not recorded | 4D8 (3beta,4alpha,5beta,14beta)-3-hydroxy-4-methylcholesta-8,24-diene-4-carboxylic acid × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；282 K；200mM MgCl2, 9%-21% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 282K
|
Resolution 1.90 Å R-free 0.213 |
| 4S15 Crystal structure of the orphan nuclear receptor RORalpha ligand-binding domain in complex with 4alpha-caboxyl, 4beta-methyl-zymosterol (4ACD8) Deposited 2015-01-08 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain D
499–510（12 aa）
Fragment：LxxLL binding motif
|
Not recorded | 4D8 (3beta,4alpha,5beta,14beta)-3-hydroxy-4-methylcholesta-8,24-diene-4-carboxylic acid × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；282 K；200mM MgCl2, 9%-21% PEG 3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 282K
|
Resolution 1.90 Å R-free 0.213 |
| 5NTN Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain P
493–512（20 aa）
|
Not recorded | 98H (5R,10S,13R,14R,17R)-17-((R,E)-7-hydroxy-6-methylhept-5-en-2-yl)-4,4,10,13,14-pentamethyl-1,2,5,6,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,7(4H)-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；14% PEG 3350, 0.04M NaFormate
|
Resolution 1.90 Å R-free 0.225 |
| 5NTN Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain Q
493–512（20 aa）
|
Not recorded | 98H (5R,10S,13R,14R,17R)-17-((R,E)-7-hydroxy-6-methylhept-5-en-2-yl)-4,4,10,13,14-pentamethyl-1,2,5,6,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,7(4H)-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；14% PEG 3350, 0.04M NaFormate
|
Resolution 1.90 Å R-free 0.225 |
| 5NTN Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain R
493–512（20 aa）
|
Not recorded | 98H (5R,10S,13R,14R,17R)-17-((R,E)-7-hydroxy-6-methylhept-5-en-2-yl)-4,4,10,13,14-pentamethyl-1,2,5,6,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,7(4H)-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；14% PEG 3350, 0.04M NaFormate
|
Resolution 1.90 Å R-free 0.225 |
| 5NTN Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain S
493–512（20 aa）
|
Not recorded | 98H (5R,10S,13R,14R,17R)-17-((R,E)-7-hydroxy-6-methylhept-5-en-2-yl)-4,4,10,13,14-pentamethyl-1,2,5,6,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,7(4H)-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；14% PEG 3350, 0.04M NaFormate
|
Resolution 1.90 Å R-free 0.225 |
| 5NTW Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain P
493–512（20 aa）
|
Not recorded | 98N (S)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-7-isopropyl-6-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；24% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.64 Å R-free 0.222 |
| 5NTW Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain Q
493–512（20 aa）
|
Not recorded | 98N (S)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-7-isopropyl-6-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；24% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.64 Å R-free 0.222 |
| 5NTW Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain R
493–512（20 aa）
|
Not recorded | 98N (S)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-7-isopropyl-6-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；24% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.64 Å R-free 0.222 |
| 5NTW Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain S
493–512（20 aa）
|
Not recorded | 98N (S)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-7-isopropyl-6-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；24% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.64 Å R-free 0.222 |
| 5NU1 Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain P
493–512（20 aa）
|
Not recorded | 8YB ~{N}-[4-(3-chlorophenyl)-5-(2-chlorophenyl)carbonyl-1,3-thiazol-2-yl]-2-(4-ethylsulfonylphenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；23% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.85 Å R-free 0.256 |
| 5NU1 Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds Deposited 2017-04-28 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain Q
493–512（20 aa）
|
Not recorded | 8YB ~{N}-[4-(3-chlorophenyl)-5-(2-chlorophenyl)carbonyl-1,3-thiazol-2-yl]-2-(4-ethylsulfonylphenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；23% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.85 Å R-free 0.256 |
| 6FZU RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ("CPD-1") AND RIP140 PEPTIDE AT 1.80A Deposited 2018-03-15 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain P
493–512（20 aa）
|
Not recorded | EE8 ~{N}-(3-chloranyl-4-ethoxy-phenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.80 Å R-free 0.251 |
| 6FZU RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ("CPD-1") AND RIP140 PEPTIDE AT 1.80A Deposited 2018-03-15 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain Q
493–512（20 aa）
|
Not recorded | EE8 ~{N}-(3-chloranyl-4-ethoxy-phenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.80 Å R-free 0.251 |
| 6G05 RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-2" AND RIP140 PEPTIDE AT 1.90A Deposited 2018-03-16 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain P
493–512（20 aa）
Fragment：UNP residues 493-512
|
Not recorded | EF5 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.90 Å R-free 0.248 |
| 6G05 RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-2" AND RIP140 PEPTIDE AT 1.90A Deposited 2018-03-16 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain Q
493–512（20 aa）
Fragment：UNP residues 493-512
|
Not recorded | EF5 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.90 Å R-free 0.248 |
| 6G07 RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-9" AND RIP140 PEPTIDE AT 1.66A Deposited 2018-03-16 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain P
493–512（20 aa）
Fragment：UNP residues 493-512
|
Not recorded | EEZ ~{N}-[5-chloranyl-6-[(1~{S})-1-phenylethoxy]pyridin-3-yl]-2-(4-ethylsulfonylphenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.66 Å R-free 0.233 |
| 6G07 RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-9" AND RIP140 PEPTIDE AT 1.66A Deposited 2018-03-16 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain Q
493–512（20 aa）
Fragment：UNP residues 493-512
|
Not recorded | EEZ ~{N}-[5-chloranyl-6-[(1~{S})-1-phenylethoxy]pyridin-3-yl]-2-(4-ethylsulfonylphenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.66 Å R-free 0.233 |
| 6G07 RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-9" AND RIP140 PEPTIDE AT 1.66A Deposited 2018-03-16 | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain R
493–512（20 aa）
Fragment：UNP residues 493-512
|
Not recorded | EEZ ~{N}-[5-chloranyl-6-[(1~{S})-1-phenylethoxy]pyridin-3-yl]-2-(4-ethylsulfonylphenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.66 Å R-free 0.233 |
| 6G07 RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-9" AND RIP140 PEPTIDE AT 1.66A Deposited 2018-03-16 | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain S
493–512（20 aa）
Fragment：UNP residues 493-512
|
Not recorded | EEZ ~{N}-[5-chloranyl-6-[(1~{S})-1-phenylethoxy]pyridin-3-yl]-2-(4-ethylsulfonylphenyl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；22% PEG3350, 0.2M ammonium acetate, 0.1M bis-TRIS
|
Resolution 1.66 Å R-free 0.233 |
| 9CWN NRIP1_133 / RIP140 SxxLxxLL motif coregulator peptide with agonist GW1929 and PPARg LBD Deposited 2024-07-29 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain B
121–143（23 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293.15 K；1.6 M AmSO4, 100mM Tris pH 8.5
|
Resolution 2.70 Å R-free 0.242 |
| 9KNC Crystal structure of human ERRg LBD in complex with 6-nitroindole Deposited 2024-11-18 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain C
376–390（15 aa）
|
Not recorded | A1EF8 6-nitro-1~{H}-indole × 2 PGR R-1,2-PROPANEDIOL × 12 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30%(w/v) PEG 5000 MME 0.1M Tris 8.0 0.2M lithium sulfate
|
Resolution 1.90 Å R-free 0.232 |
| 9KND Crystal structure of human ERRg LBD in complex with indole Deposited 2024-11-18 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain B
376–390（15 aa）
|
Not recorded | IND INDOLE × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30%(w/v) PEG 5000 MME 0.1M Tris 8.0 0.2M lithium sulfate
|
Resolution 1.52 Å R-free 0.212 |
| 9KNE Crystal structure of human ERRg LBD in complex with 5-nitroindole Deposited 2024-11-18 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain B
376–390（15 aa）
|
Not recorded | 2HU 5-nitro-1H-indole × 2 PGR R-1,2-PROPANEDIOL × 8 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30%(w/v) PEG 5000 MME 0.1M Tris 8.0 0.2M lithium sulfate
|
Resolution 1.80 Å R-free 0.224 |
| 9KNF Crystal structure of human ERRg LBD in complex with 4028691 Deposited 2024-11-18 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain C
376–390（15 aa）
|
Not recorded | A1EGB 5-chloranyl-2~{H}-indazole × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.0 M K/Na tartrate, 0.1 M Tris pH 7.0, 0.2 M Li2SO4
|
Resolution 1.62 Å R-free 0.228 |
| 9KNG Crystal structure of human ERRg LBD in complex with 4034496 Deposited 2024-11-18 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain C
376–390（15 aa）
|
Not recorded | A1EGD 6-methyl-1,3-benzothiazole-2,4-diamine × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30%(w/v) PEG 5000 MME, 0.1M Tris 8.0, 0.2M lithium sulfate
|
Resolution 1.50 Å R-free 0.234 |